메뉴 건너뛰기




Volumn 17, Issue 5, 2011, Pages 721-728

Haemophilia management: Time to get personal?

Author keywords

Antigen presentation repertoire; Factor VIII inhibitor; Haemophilia A; HLA class II; Non synonymous SNPs; Pharmacogenetics

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN;

EID: 80052024050     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02517.x     Document Type: Review
Times cited : (14)

References (47)
  • 1
    • 0035822038 scopus 로고    scopus 로고
    • The hemophilias - from royal genes to gene therapy
    • Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
    • (2001) N Engl J Med , vol.344 , pp. 1773-1779
    • Mannucci, P.M.1    Tuddenham, E.G.2
  • 2
    • 34247625634 scopus 로고    scopus 로고
    • Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors
    • Dasgupta S, Navarrete AM, Delignat S et al. Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors. Immunol Lett 2007; 110: 23-8.
    • (2007) Immunol Lett , vol.110 , pp. 23-28
    • Dasgupta, S.1    Navarrete, A.M.2    Delignat, S.3
  • 3
    • 0028268941 scopus 로고
    • Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates
    • de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
    • (1994) Thromb Haemost , vol.71 , pp. 544-547
    • de Biasi, R.1    Rocino, A.2    Papa, M.L.3    Salerno, E.4    Mastrullo, L.5    De Blasi, D.6
  • 4
    • 0026548917 scopus 로고
    • Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
    • Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
    • (1992) Lancet , vol.339 , pp. 594-598
    • Ehrenforth, S.1    Kreuz, W.2    Scharrer, I.3
  • 5
    • 0141482007 scopus 로고    scopus 로고
    • Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
    • Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
    • (2003) Blood , vol.102 , pp. 2358-2363
    • Gringeri, A.1    Mantovani, L.G.2    Scalone, L.3    Mannucci, P.M.4
  • 7
    • 70349310353 scopus 로고    scopus 로고
    • Factor VIII inhibitors: risk factors and methods for prevention and immune modulation
    • Zhang AH, Skupsky J, Scott DW. Factor VIII inhibitors: risk factors and methods for prevention and immune modulation. Clin Rev Allergy Immunol 2009; 37: 114-24.
    • (2009) Clin Rev Allergy Immunol , vol.37 , pp. 114-124
    • Zhang, A.H.1    Skupsky, J.2    Scott, D.W.3
  • 8
    • 34247330151 scopus 로고    scopus 로고
    • A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels
    • Viel KR, Machiah DK, Warren DM et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007; 109: 3713-24.
    • (2007) Blood , vol.109 , pp. 3713-3724
    • Viel, K.R.1    Machiah, D.K.2    Warren, D.M.3
  • 9
    • 0031598278 scopus 로고    scopus 로고
    • Inhibitors occur more frequently in African-American and Latino haemophiliacs
    • Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
    • (1998) Haemophilia , vol.4 , pp. 68
    • Aledort, L.M.1    Dimichele, D.M.2
  • 10
    • 6644227418 scopus 로고    scopus 로고
    • The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
    • Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
    • (2001) Haemophilia , vol.7 , pp. 267-272
    • Astermark, J.1    Berntorp, E.2    White, G.C.3    Kroner, B.L.4
  • 11
    • 0028266130 scopus 로고
    • A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group
    • Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
    • (1994) Blood , vol.83 , pp. 2428-2435
    • Bray, G.L.1    Gomperts, E.D.2    Courter, S.3
  • 12
    • 0027473752 scopus 로고
    • Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group
    • Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
    • (1993) N Engl J Med , vol.328 , pp. 453-459
    • Lusher, J.M.1    Arkin, S.2    Abildgaard, C.F.3    Schwartz, R.S.4
  • 13
    • 64749096663 scopus 로고    scopus 로고
    • Inhibitors of factor VIII in black patients with hemophilia
    • Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
    • (2009) N Engl J Med , vol.360 , pp. 1618-1627
    • Viel, K.R.1    Ameri, A.2    Abshire, T.C.3
  • 15
    • 35348983887 scopus 로고    scopus 로고
    • A second generation human haplotype map of over 3.1 million SNPs
    • Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-61.
    • (2007) Nature , vol.449 , pp. 851-861
    • Frazer, K.A.1    Ballinger, D.G.2    Cox, D.R.3
  • 16
    • 0035094764 scopus 로고    scopus 로고
    • Variation is the spice of life
    • Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27: 234-6.
    • (2001) Nat Genet , vol.27 , pp. 234-236
    • Kruglyak, L.1    Nickerson, D.A.2
  • 17
    • 80052032429 scopus 로고    scopus 로고
    • 'Personalized Medicine' may get a boost
    • Nov. 29, pg. A2.
    • Alonso-Zaldivar R. 'Personalized Medicine' may get a boost. Boston Globe, Nov. 29, 2008 pg. A2.
    • (2008) Boston Globe
    • Alonso-Zaldivar, R.1
  • 18
    • 75549084134 scopus 로고    scopus 로고
    • Personalized genomic information: preparing for the future of genetic medicine
    • Guttmacher AE, McGuire AL, Ponder B, Stefansson K. Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet 2010; 11: 161-5.
    • (2010) Nat Rev Genet , vol.11 , pp. 161-165
    • Guttmacher, A.E.1    McGuire, A.L.2    Ponder, B.3    Stefansson, K.4
  • 19
    • 2342459714 scopus 로고    scopus 로고
    • Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
    • Innocenti F, Undevia SD, Iyer L et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-8.
    • (2004) J Clin Oncol , vol.22 , pp. 1382-1388
    • Innocenti, F.1    Undevia, S.D.2    Iyer, L.3
  • 20
    • 21144448879 scopus 로고    scopus 로고
    • Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
    • Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
    • (2005) N Engl J Med , vol.352 , pp. 2285-2293
    • Rieder, M.J.1    Reiner, A.P.2    Gage, B.F.3
  • 21
    • 27444443859 scopus 로고    scopus 로고
    • Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics
    • Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005; 15: 801-15.
    • (2005) Pharmacogenet Genomics , vol.15 , pp. 801-815
    • Salavaggione, O.E.1    Wang, L.2    Wiepert, M.3    Yee, V.C.4    Weinshilboum, R.M.5
  • 22
    • 27744463332 scopus 로고    scopus 로고
    • Pharmacogenetics/genomics and personalized medicine
    • Spec No. 2: -
    • Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005; 14 Spec No. 2: R207-14.
    • (2005) Hum Mol Genet , vol.14
    • Sadee, W.1    Dai, Z.2
  • 23
    • 73649109224 scopus 로고    scopus 로고
    • 10years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal
    • Kurnik D, Loebstein R, Halkin H, Gak E, Almog S. 10years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 2009; 10: 1955-65.
    • (2009) Pharmacogenomics , vol.10 , pp. 1955-1965
    • Kurnik, D.1    Loebstein, R.2    Halkin, H.3    Gak, E.4    Almog, S.5
  • 24
    • 33745961962 scopus 로고    scopus 로고
    • Protein therapeutics: new applications for pharmacogenetics
    • Krejsa C, Rogge M, Sadee W. Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov 2006; 5: 507-21.
    • (2006) Nat Rev Drug Discov , vol.5 , pp. 507-521
    • Krejsa, C.1    Rogge, M.2    Sadee, W.3
  • 25
    • 0031804517 scopus 로고    scopus 로고
    • The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4
    • Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res 1998; 26: 216-9.
    • (1998) Nucleic Acids Res , vol.26 , pp. 216-219
    • Kemball-Cook, G.1    Tuddenham, E.G.2    Wacey, A.I.3
  • 26
    • 0042626369 scopus 로고    scopus 로고
    • The incidence of inhibitor development according to specific mutations--and treatment?
    • Goodeve A. The incidence of inhibitor development according to specific mutations--and treatment? Blood Coagul Fibrinolysis 2003; 14(Suppl. 1): S17-21.
    • (2003) Blood Coagul Fibrinolysis , vol.14 , Issue.SUPPL. 1
    • Goodeve, A.1
  • 27
    • 0031856491 scopus 로고    scopus 로고
    • Factor VIII inhibitors in mild and moderate-severity haemophilia A
    • Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
    • (1998) Haemophilia , vol.4 , pp. 558-563
    • Hay, C.R.1
  • 28
    • 33751014075 scopus 로고    scopus 로고
    • Genetic risk factors for inhibitors to factors VIII and IX
    • Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl. 6): 15-22.
    • (2006) Haemophilia , vol.12 , Issue.SUPPL. 6 , pp. 15-22
    • Oldenburg, J.1    Pavlova, A.2
  • 29
    • 0033121017 scopus 로고    scopus 로고
    • Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A
    • Peerlinck K, Jacquemin MG, Arnout J et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999; 93: 2267-73.
    • (1999) Blood , vol.93 , pp. 2267-2273
    • Peerlinck, K.1    Jacquemin, M.G.2    Arnout, J.3
  • 30
    • 0034969121 scopus 로고    scopus 로고
    • The manufacturing process for B-domain deleted recombinant factor VIII
    • Eriksson RK, Fenge C, Lindner-Olsson E et al. The manufacturing process for B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 24-31.
    • (2001) Semin Hematol , vol.38 , pp. 24-31
    • Eriksson, R.K.1    Fenge, C.2    Lindner-Olsson, E.3
  • 31
    • 0038383605 scopus 로고    scopus 로고
    • The epidemiology of inhibitors in haemophilia A: a systematic review
    • Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
    • (2003) Haemophilia , vol.9 , pp. 418-435
    • Wight, J.1    Paisley, S.2
  • 32
    • 77955492929 scopus 로고    scopus 로고
    • Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
    • Mei B, Pan C, Jiang H et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
    • (2010) Blood , vol.116 , pp. 270-279
    • Mei, B.1    Pan, C.2    Jiang, H.3
  • 33
    • 53449102958 scopus 로고    scopus 로고
    • Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa
    • Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res 2008; 122(Suppl. 4): S14-9.
    • (2008) Thromb Res , vol.122 , Issue.SUPPL. 4
    • Schulte, S.1
  • 34
    • 77949884124 scopus 로고    scopus 로고
    • Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR
    • Suzuki T, Ishii-Watabe A, Tada M et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184: 1968-76.
    • (2010) J Immunol , vol.184 , pp. 1968-1976
    • Suzuki, T.1    Ishii-Watabe, A.2    Tada, M.3
  • 36
    • 0027520025 scopus 로고
    • Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A
    • Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5: 236-41.
    • (1993) Nat Genet , vol.5 , pp. 236-241
    • Lakich, D.1    Kazazian Jr, H.H.2    Antonarakis, S.E.3    Gitschier, J.4
  • 37
  • 39
    • 0029095603 scopus 로고
    • Factor VIII gene inversions in severe hemophilia A: results of an international consortium study
    • Antonarakis SE, Rossiter JP, Young M et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-12.
    • (1995) Blood , vol.86 , pp. 2206-2212
    • Antonarakis, S.E.1    Rossiter, J.P.2    Young, M.3
  • 40
    • 0034651552 scopus 로고    scopus 로고
    • Prevention and treatment of factor VIII inhibitors in murine hemophilia A
    • Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
    • (2000) Blood , vol.95 , pp. 1324-1329
    • Qian, J.1    Collins, M.2    Sharpe, A.H.3    Hoyer, L.W.4
  • 41
    • 0035139983 scopus 로고    scopus 로고
    • Danger signals: SOS to the immune system
    • Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114-9.
    • (2001) Curr Opin Immunol , vol.13 , pp. 114-119
    • Gallucci, S.1    Matzinger, P.2
  • 42
    • 0036951207 scopus 로고    scopus 로고
    • Genetics of the immune response: identifying immune variation within the MHC and throughout the genome
    • Geraghty DE, Daza R, Williams LM, Vu Q, Ishitani A. Genetics of the immune response: identifying immune variation within the MHC and throughout the genome. Immunol Rev 2002; 190: 69-85.
    • (2002) Immunol Rev , vol.190 , pp. 69-85
    • Geraghty, D.E.1    Daza, R.2    Williams, L.M.3    Vu, Q.4    Ishitani, A.5
  • 43
    • 58149123374 scopus 로고    scopus 로고
    • HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population
    • Mack SJ, Tu B, Lazaro A et al. HLA-A, -B, -C, and -DRB1 allele and haplotype frequencies distinguish Eastern European Americans from the general European American population. Tissue Antigens 2009; 73: 17-32.
    • (2009) Tissue Antigens , vol.73 , pp. 17-32
    • Mack, S.J.1    Tu, B.2    Lazaro, A.3
  • 44
    • 33845914334 scopus 로고    scopus 로고
    • HLA-A, -B, -C, -DRB1 allele and haplotype frequencies in an African American population
    • Tu B, Mack SJ, Lazaro A et al. HLA-A, -B, -C, -DRB1 allele and haplotype frequencies in an African American population. Tissue Antigens 2007; 69: 73-85.
    • (2007) Tissue Antigens , vol.69 , pp. 73-85
    • Tu, B.1    Mack, S.J.2    Lazaro, A.3
  • 45
    • 70349328358 scopus 로고    scopus 로고
    • Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses
    • Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009; 114: 1423-8.
    • (2009) Blood , vol.114 , pp. 1423-1428
    • Ettinger, R.A.1    James, E.A.2    Kwok, W.W.3    Thompson, A.R.4    Pratt, K.P.5
  • 46
    • 77953176040 scopus 로고    scopus 로고
    • HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P
    • Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P. Haemophilia 2010; 16: 44-55.
    • (2010) Haemophilia , vol.16 , pp. 44-55
    • Ettinger, R.A.1    James, E.A.2    Kwok, W.W.3    Thompson, A.R.4    Pratt, K.P.5
  • 47
    • 36349021392 scopus 로고    scopus 로고
    • T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide
    • James EA, Kwok WW, Ettinger RA, Thompson AR, Pratt KP. T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide. J Thromb Haemost 2007; 5: 2399-407.
    • (2007) J Thromb Haemost , vol.5 , pp. 2399-2407
    • James, E.A.1    Kwok, W.W.2    Ettinger, R.A.3    Thompson, A.R.4    Pratt, K.P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.